-
Mashup Score: 2
IMF Chief Scientific Officer Dr. Brian G.M. Durie discusses the details and outcome of the recent April 12th Oncologic Drugs Advisory Committee meeting on “the use of minimal residual disease (MRD) as an endpoint in multiple myeloma clinical trials, including considerations regarding timing of assessment, patient populations, and trial design for future studies that intend to use MRD to support accelerated approval of a new product or a new indication.”
Source: www.myeloma.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1International Myeloma Foundation - 4 month(s) ago
{node:summary]
Source: www.myeloma.orgCategories: General Medicine News, PayerTweet
-
Mashup Score: 2
IMF Chief Scientific Officer Dr. Brian G.M. Durie discusses the details and outcome of the recent April 12th Oncologic Drugs Advisory Committee meeting on “the use of minimal residual disease (MRD) as an endpoint in multiple myeloma clinical trials, including considerations regarding timing of assessment, patient populations, and trial design for future studies that intend to use MRD to support accelerated approval of a new product or a new indication.”
Source: www.myeloma.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 30M-Power New York: Community Workshop 2024 - 7 month(s) ago
Don’t miss this New York community event to discuss health empowerment. We will focus on awareness of multiple myeloma in the African American community. The panel will share patient stories and suggestions to “M-Power” yourself if ever faced with a complicated diagnosis. Refreshments will be provided.
Source: www.myeloma.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Top Myeloma Research Presented at ASCO & EHA Webinar 2024 - 7 month(s) ago
Discover the top multiple myeloma research presented at ASCO and EHA 2024 in this informative webinar.
Source: www.myeloma.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 8IMWG Scientific and Working Committees - 7 month(s) ago
The International Myeloma Working Group has a scientific committee and a few working committees. Here are their members.
Source: www.myeloma.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 21International Myeloma Working Group (IMWG) Publications - 7 month(s) ago
The International Myeloma Working Group (IMWG) has published dozens of research studies and treatment guidelines on multiple myeloma and its related disorders. The following are a sample of the International Myeloma Working Group’s ranging publication topics:
Source: www.myeloma.orgCategories: General Medicine News, Hem/OncsTweet-
@paurotero @JKaufmanMD @szusmani @YiLinMDPhD @TomBmt133 @DrRakeshPopat @AjayNookaMD @H_Einsele @SurbhiSidanaMD @AjaiChari @End_myeloma @KweeYong2 @NoopurRajeMD @jmikhaelmd @chngwj @MyelomaOslo @JaimeLarraya @IMFmyeloma Here is a link to all prior IMWG guidelines and consensus statements. https://t.co/OsCjtEigdJ
-
-
Mashup Score: 4IMWG Scientific and Working Committees - 7 month(s) ago
The International Myeloma Working Group has a scientific committee and a few working committees. Here are their members.
Source: www.myeloma.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 21International Myeloma Working Group (IMWG) Publications - 7 month(s) ago
The International Myeloma Working Group (IMWG) has published dozens of research studies and treatment guidelines on multiple myeloma and its related disorders. The following are a sample of the International Myeloma Working Group’s ranging publication topics:
Source: www.myeloma.orgCategories: General Medicine News, Hem/OncsTweet-
@paurotero @JKaufmanMD @szusmani @YiLinMDPhD @TomBmt133 @DrRakeshPopat @AjayNookaMD @H_Einsele @SurbhiSidanaMD @AjaiChari @End_myeloma @KweeYong2 @NoopurRajeMD @jmikhaelmd @chngwj @MyelomaOslo @JaimeLarraya @IMFmyeloma Here is a link to all prior IMWG guidelines and consensus statements. https://t.co/OsCjtEigdJ
-
-
Mashup Score: 2
IMF Chief Scientific Officer Dr. Brian G.M. Durie discusses the details and outcome of the recent April 12th Oncologic Drugs Advisory Committee meeting on “the use of minimal residual disease (MRD) as an endpoint in multiple myeloma clinical trials, including considerations regarding timing of assessment, patient populations, and trial design for future studies that intend to use MRD to support accelerated approval of a new product or a new indication.”
Source: www.myeloma.orgCategories: General Medicine News, Hem/OncsTweet
A Historic Turning Point: ODAC Unanimously Votes [4/12/24] in Favor of MRD Testing as an Early Endpoint in Myeloma Clinical Trials to Support Accelerated Approvals of New Treatments [Apr 18, 2024] @IMFmyeloma https://t.co/eDOgIrqt4p #mmMRD #mmsm #ctsm @FDAOncology https://t.co/cABSxMTt0d